Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Want to see GB:AGY full AI Analyst Report?
Top Page
Allergy Therapeutics
(LSE:AGY)
Select Model
Select Model
Rating:45Neutral
Price Target:
11.00 p
▼(-6.78% Downside)
Action:ReiteratedDate:02/20/26
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Focused niche product portfolio
A clear, focused business model on allergy immunotherapy creates durable competitive advantages: deep domain expertise, targeted R&D, and tailored commercial pathways. Specialization supports higher barriers to entry, reproducible clinical know-how, and long-term customer relationships with clinics and allergists.
Negative Factors
Declining revenue trend
Sustained revenue decline erodes the commercial base needed to fund R&D and scale manufacturing. A shrinking top line reduces operating leverage, limits reinvestment capacity, and makes it harder to absorb fixed costs, increasing reliance on external financing to sustain operations over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused niche product portfolio
A clear, focused business model on allergy immunotherapy creates durable competitive advantages: deep domain expertise, targeted R&D, and tailored commercial pathways. Specialization supports higher barriers to entry, reproducible clinical know-how, and long-term customer relationships with clinics and allergists.
Read all positive factors
Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£687.08M
Dividend YieldN/A
Average Volume (3M)460.33K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth2.94%
EPS Growth-32.00%
CountryUK
Employees612
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Allergy Therapeutics Business Overview & Revenue Model
Company Description
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-re...
How the Company Makes Money
Allergy Therapeutics generates revenue primarily through the sale of its allergy immunotherapy products, which are marketed directly to healthcare providers and clinics. The company also benefits from partnerships with pharmaceutical companies and...
Allergy Therapeutics Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.29M | 55.04M | 55.20M | 59.59M | 72.77M | 84.33M |
| Gross Profit | 23.59M | 25.13M | 29.74M | 32.69M | 48.95M | 61.80M |
| EBITDA | -32.73M | -29.43M | -30.74M | -36.24M | -8.69M | 7.61M |
| Net Income | -48.97M | -40.13M | -40.22M | -43.07M | -13.78M | 2.89M |
Balance Sheet | ||||||
| Total Assets | 71.00M | 67.54M | 64.83M | 66.77M | 72.95M | 88.09M |
| Cash, Cash Equivalents and Short-Term Investments | 10.08M | 12.79M | 12.91M | 14.85M | 20.52M | 40.27M |
| Total Debt | 26.75M | 60.09M | 30.99M | 35.99M | 10.53M | 11.17M |
| Total Liabilities | 66.75M | 95.74M | 61.12M | 64.70M | 35.18M | 39.55M |
| Stockholders Equity | 4.25M | -28.19M | 3.71M | 2.07M | 37.77M | 48.53M |
Cash Flow | ||||||
| Free Cash Flow | -37.34M | -31.98M | -35.54M | -35.59M | -17.17M | 5.95M |
| Operating Cash Flow | -32.80M | -28.72M | -32.14M | -30.92M | -14.11M | 8.52M |
| Investing Cash Flow | -4.46M | -3.15M | -1.20M | -4.67M | -3.06M | -2.76M |
| Financing Cash Flow | 26.01M | 32.04M | 31.43M | 29.91M | -2.64M | -2.03M |
Allergy Therapeutics Technical Analysis
Negative
11.80
Price Trends
10.89
Negative
11.05
Negative
9.67
Positive
Market Momentum
-0.08
Negative
45.30
Neutral
69.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Negative. The current price of 11.8 is above the 20-day moving average (MA) of 10.53, above the 50-day MA of 10.89, and above the 200-day MA of 9.67, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 69.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGY.
Allergy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £228.89M | 32.32 | 2.63% | 2.18% | 20.04% | -46.44% | |
60 Neutral | £66.40M | 2.80 | 7.82% | ― | ― | ― | |
59 Neutral | £3.04B | 6.96 | 15.83% | 4.16% | 3.84% | 8.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £73.29M | -3.21 | 103.62% | ― | 49.81% | 52.94% | |
45 Neutral | £687.08M | -7.21 | 409.00% | ― | 2.94% | -32.00% |
* Healthcare Sector Average
GB:AGY
Allergy Therapeutics
10.85
3.75
52.82%
GB:ANCR
Animalcare
331.50
84.59
34.26%
GB:HIK
Hikma Pharmaceuticals
1,417.50
-454.97
-24.30%
GB:STX
Shield Therapeutics
6.86
4.17
155.02%
GB:VLG
Venture Life
54.50
5.20
10.55%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
42.50
6.50
18.06%
Allergy Therapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Allergy Therapeutics Reshapes Major Shareholding Ahead of Potential Hong Kong Listing
Positive
Mar 12, 2026
Allergy Therapeutics has reported an internal reorganisation within major shareholder ZQ Group, which transferred most of the company’s shares from SkyGem Acquisition to SkyGem International Holdings without changing ultimate beneficial owne...
Business Operations and Strategy
Allergy Therapeutics’ VLP Peanut Shows Strong Immune Response in Early-Stage Trial
Positive
Mar 4, 2026
Allergy Therapeutics reported positive biomarker data from its Phase I/IIa PROTECT trial of VLP Peanut, showing strong and consistent immunomodulating effects in peanut-allergic subjects. Higher doses produced marked reductions in basophil sensiti...
Business Operations and StrategyProduct-Related Announcements
Allergy Therapeutics showcases new allergy immunotherapy data at AAAAI 2026
Positive
Feb 26, 2026
Allergy Therapeutics will present new clinical and biomarker data from its pollen and food-allergy research pipeline at the 2026 American Academy of Allergy, Asthma Immunology Annual Meeting in Philadelphia. The company emphasised that no new pri...
Business Operations and StrategyPrivate Placements and Financing
Allergy Therapeutics seals £40m Hayfin facility and simplifies capital structure
Positive
Feb 23, 2026
Allergy Therapeutics has amended its existing loan agreement with Hayfin, replacing an uncommitted £20m line with a new committed £40m senior secured facility, giving the company £60m of total debt and at least 12 months of working ...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing Changes
Allergy Therapeutics Bolsters Board and Strategy Team to Drive Global Expansion
Positive
Jan 30, 2026
Allergy Therapeutics has strengthened its leadership and governance structure with the appointment of veteran investment banker Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and healthcare finance specialist Lawrence Alle...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Allergy Therapeutics Wins Strong Shareholder Backing at 2026 AGM
Positive
Jan 29, 2026
Allergy Therapeutics plc reported that all resolutions at its 2026 Annual General Meeting were passed on a show of hands, reflecting strong shareholder backing for the company’s governance and strategic direction. Shareholders approved the 2...
Business Operations and StrategyExecutive/Board Changes
Allergy Therapeutics Grants Performance-Linked Share Options to Senior Management
Positive
Jan 28, 2026
Allergy Therapeutics has granted new share options under its long-term incentive plan to key members of its management team, including CEO Manuel Llobet and CFO Shaun Furlong, as part of a strategy to drive long-term value creation and align leade...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Allergy Therapeutics lifts revenues and launches Grassmuno as German TAV transition accelerates
Positive
Jan 19, 2026
Allergy Therapeutics reported a strong first half to its 2026 financial year, with revenues rising 7% to £36.3 million despite the ongoing phase-out of older unregistered products in Germany under the TAV programme, underlining renewed growth...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesShareholder Meetings
Allergy Therapeutics Adds Asia-Focused Expertise to Board Ahead of Potential Hong Kong Listing
Positive
Jan 6, 2026
Allergy Therapeutics has published the notice of its 2025 Annual General Meeting, following release of its annual report and accounts for the year ended 30 June 2025, with meeting documents now available to shareholders via the company’s web...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Allergy Therapeutics Wins Shareholder Mandate for Potential Equity Raise Ahead of Hong Kong Dual Listing
Positive
Dec 29, 2025
Allergy Therapeutics has secured shareholder approval at its general meeting to allot up to 610 million new ordinary shares, representing around 10% of its existing share capital, and to disapply pre-emption rights, giving the board flexibility to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.